63rd ASH Annual Meeting and Exposition
December 11-14, 2021
  • Targeted Therapy in Low Grade Lymphoma
  • Evolution of Immunotherapeutic Regimens in B-cell Lymphomas
  • Front-line Induction Therapy and Novel Agents After Relapse
  • Advances in Treatment Approaches

623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy in Low Grade Lymphoma


Jae H Park, Eric S. Winer, Scott F. Huntington, et al.

The chemotherapy-free combination of vemurafenib plus obinutuzumab induced a CR rate of 100% with high MRD negativity (96%) in patients with hairy cell leukemia (HCL) in the frontline setting. According to the authors, this is a promising targeted therapeutic approach for HCL. In most patients, normalization of cytopenia was observed after the 4-week lead-in of vemurafenib. There were no cases of febrile neutropenia and there was no evidence of significant T-cell immunosuppression during the course of therapy.


Tycel Phillips, Abraham Avigdor, Ronit Gurion, et al.

In patients with R / R-MZL, parsaclisib monotherapy resulted in a rapid and durable clinical response, generally good tolerability with a manageable safety profile. The authors suggest that parsaclisib could be a potential treatment option for R / R MZL.



Julio C. Chavez, Neta Goldschmidt, Felipe Samaniego, et al.

U2 had improved efficacy in patients with R / R-MZL and was highly active compared to a previous cohort of MZL patients treated with umbra mono in this study. With the U2 combination, there was a relatively low incidence of immune-mediated toxicities and AEs-related discontinuations.



Daobin Zhou, Jie Jin, Zheng-zheng Fu, et al.

In this short-term follow-up, orelabrutinib demonstrated significant efficacy in the treatment of R/R WM patients with a favorable safety and tolerability profile with limited side effects. According to the study authors, orelabrutinib has the potential to be a promising treatment option for WM patients.



Zrinka Sertić, Marko Lucijanic, Sandra Bašić-Kinda, et al.

It is known that patients with haematological diseases have poorer serological response rates to SARS-CoV-2 vaccines. The study results suggest that patients benefit from receiving both vaccine doses with no significant difference between vaccine types. Patients in active treatment with non-Hodgkin’s lymphoma without prior HSCT who received anti-CD20 mAb seem to be more likely to be seronegative after receiving both doses



Giulia Benevolo, Simone Ferrero, Nicoletta Villivà, et al.

The novel BRB combination as a second-line therapy has strong anti-tumor activity and is an effective and well-tolerated salvage treatment for RR-WM patients. This is demonstrated by an absolute increase in the PFS rate compared to historical controls (30-month PFS of 79%) and by high clinical response rates with an ORR (CR + VGPR + PR) of 82% (95% CI 66-92). MRD monitoring demonstrates the promising efficacy of BRB therapy in eliminating residual disease.

623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B-cell Lymphomas


L. Elizabeth Budde, Laurie H. Sehn, Matthew Matasar, et al.

With Mosun, high response rates are achieved in patients with 3L + R/R FL, including patients with POD24 and/or double refractory disease (ORR: 78.9%; CR: 57.8%), in the majority of patients 12 months. Mosun induces deep and permanent remissions with a manageable safety profile. The C1 step-up dosing effectively attenuates CRS and thus allows treatment without mandatory hospitalization. The study authors conclude that Mosun is an active new therapy for 3L + R/R FL.



Franck Morschhauser, Carmelo Carlo-Stella, Michael Dickinson, et al.

Glofitamab SUD monotherapy or combined with obinutuzumab achieved high response rates in patients with heavily pretreated R/R FL, including high-risk subgroups. They were comparable to the CAR-T on R/ R FL data. With a manageable safety profile of glofitamab, CRS events were mostly of low grade and mainly occurred in C1 and C2. Further analyzes will be presented in the oral session.



Franck Morschhauser, Mark Bishton, Toby A. Eyre, et al.

Encouraging preliminary anti-lymphoma activity has been observed in M + Len with an acceptable safety profile in patients with R / R FL with at least one prior line of therapy. Updated data on safety, efficacy and pharmacokinetics will be presented in the oral session.



Tycel Phillips, Michael Dickinson, Franck Morschhauser, et al.

With manageable and low-grade CRS rates, glofitamab SUD as Gpt monotherapy induced high response rates in patients with MCL. Most had previously failed BTKi therapy. ICANS-like AEs were rare, mild, and resolved within a day. There were no discontinuations of treatment due to AE. Further analyzes will be presented in the oral session.



Catherine Thieblemont, Michael Dickinson, Joaquin Martinez-Lopez, et al.

Tisagenlecleucel produced high ORR and CRR and was associated with sustained response and promising 12 month PFS in patients with r/r FL and 2+ previous lines of therapy. The median follow-up was 17 months.



Elizabeth Budde, Ajay K Gopal, Won Seog Kim, et al.

IGM-2323 shows an excellent safety and tolerability profile up to 1000 mg with clinical activity across several histologies. The incidence of CRS was reduced when IGM-2323 was administered on a dose titration schedule. Updated safety, PK, biomarker, and efficacy data, including full dose-escalation data, will be presented in the oral session.


623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Front-line Induction Therapy and Novel Agents After Relapse


Vincent Ribrag, Violaine Safar, Hanneke Kluin-Nelemans, et al.

In patients responding to induction immunochemotherapy, R2M is better than RM for PFS but not for OS. Safety data in the R2M arm show higher toxicity.



Olivier Hermine, Linmiao Jiang, Jan Walewski, et al.

The results on the first-line treatment of MCL patients under 66 years of age confirm the previously observed, significantly prolonged TTF due to the addition of high-dose ARA-C within a further median follow-up period of 5 years. With their data, the authors suggest that some patients can be functionally cured by optimal first-line treatment and may question future chemotherapy-free strategies in MCL.



Michael Wang, Nirav N. Shah, Alvaro J. Alencar, et al.

In heavily pretreated MCL with a poor prognosis after several previous lines of therapy, the well-tolerated (and with a wide therapeutic index) pirtobrutinib showed promising efficacy. Updated data will be presented in the oral session.



Amitkumar Mehta, Marek Trněný, Jan Walewski, et al.

Monotherapy with parsaclisib resulted in a rapid and sustained response. Parsaclisib had an acceptable safety profile and was generally well tolerated by BTK inhibitor-naïve patients with R / R-MCL. The authors' data suggest that parsaclisib could be a potential treatment option for patients with R / R-MCL.



Martin Dreyling, Eva Hoster, Kamal Bouabdallah, et al.

The addition of bortezomib resulted in R-HAD increasing the time to treatment failure. This was mainly due to higher response rates. Relevant differences or long-term effects in terms of survival or toxicities were not observed.



Maria Chiara Tisi, Luca Nassi, Caterina Patti, et al.

R-BAC has sustained efficacy over time in elderly patients with newly diagnosed MCL, with a median OS of over 60 percent at 7 years. Thus, this regimen, which compared favorably to any other reported immunochemotherapy regimen (with or without maintenance therapy) in similar populations, has significantly affected the life expectancy of elderly patients with MCL.

623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Follicular Lymphoma: Advances in Treatment Approaches


Stefano Luminari, Maria Elena Nizzoli, Annalisa Chiarenza, et al.

Regardless of the regimen prescribed, the FOLL12 study demonstrated the superiority of the standard RM over the response-adapted management after induction in patients with high tumor burden follicular lymphoma treated with RB. This study thus provides the first prospective, non-randomized evidence of RM effectiveness. Both regimens, R-CHOP and RB, had similar efficacy profiles.



Frederick Lansigan, David Jacob Andorsky, Morton Coleman, et al.

This complete analysis of all patients in the induction phase of MAGNIFY further suggests that R2 with its tolerable safety profile is active in patients with R / R FL grade 1-3a and MZL. This includes also rituximab-refractory, double-refractory, and early relapse patients.



Ryan C. Lynch, Abraham Avigdor, Matthew S McKinney, et al.

Parsaclisib monotherapy showed a rapid, sustained response in patients with R/R FL. Parsaclisib had an acceptable safety profile and was generally well tolerated. With these data, the authors suggest that parsaclisib may be a favorable treatment option for patients with R/R FL.



Craig A. Portell, Opeyemi Jegede, Nina D. Wagner-Johnston, et al.

The Study reached its primary endpoint, but the combination of OB-VEN with 800 mg for 10 days plus mO unfortunately does not show an acceptable benefit-risk profile.



Brad S. Kahl, Fangxin Hong, Christopher Peterson, et al.

In treatment-naïve follicular lymphoma with a low tumor burden, MR was superior to RR in terms of delay to first cytotoxic therapy and response time. There has been a trend towards reducing the risk of histological transformation. MR did not improve overall survival. Rituximab was highly effective in delaying the time to first cytotoxic therapy in both dosing strategies.



Brendan Beaton, Sarah C Sasson, Katherine Rankin, et al.

Treatment-naive patients (TNP) had a better response than treated patients in the FL cohort, but not significantly different from healthy controls. WM-patients with BTKi had a significantly reduced response compared to TNP. The same reduction was not observed in patients with chemotherapy-rituximab. FL patients with chemotherapy-rituximab had a significantly reduced response compared to TNP. The full dates will be presented in the oral session.


  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos


Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.




Copyright 2024. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close